oasis 1 oral semaglutide 50 mg obesity nejm 2023 taken once per day in adults with overweight or (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial Novel strategies for medical management

GLP-1 therapy has been linked to improved inflammatory markers (like Hs-CRP), metabolic markers (like HbA1C), and lipid/cholesterol markers (like HDL and LDL)

Which peptide will you choose on your journey to defy aging

Never freeze reconstituted peptide solutions, as the freeze-thaw cycle causes aggregation and loss of activity

Alison Stewart: If you are interested in the long-term questions, you should listen to Virgie Tovar's podcast, GLP-1 Truth Serum

2013 FDA safety communication reviewing data on pancreatic cancer risk

Semaglutide and Tirzepatide is FDA-approved and is an injection that suppresses the appetite and assists in weight loss management